MiMedx Group, Inc (MDXG): Price and Financial Metrics
GET POWR RATINGS... FREE!
MDXG POWR Grades
- MDXG scores best on the Sentiment dimension, with a Sentiment rank ahead of 97.49% of US stocks.
- The strongest trend for MDXG is in Value, which has been heading up over the past 179 days.
- MDXG ranks lowest in Momentum; there it ranks in the 16th percentile.
MDXG Stock Summary
- Mimedx Group Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 100% of US listed stocks.
- MDXG's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 0.71% of US stocks.
- The volatility of Mimedx Group Inc's share price is greater than that of 94.35% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Mimedx Group Inc are EXPR, ABC, FTDR, CHWY, and PTCT.
- Visit MDXG's SEC page to see the company's official filings. To visit the company's web site, go to www.mimedx.com.
MDXG Valuation Summary
- MDXG's EV/EBIT ratio is -20.6; this is 170.31% lower than that of the median Healthcare stock.
- Over the past 165 months, MDXG's EV/EBIT ratio has gone up 906.4.
- MDXG's EV/EBIT ratio has moved up 906.4 over the prior 165 months.
Below are key valuation metrics over time for MDXG.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MDXG | 2021-08-31 | 6.3 | -231.5 | -19.9 | -20.6 |
| MDXG | 2021-08-30 | 6.3 | -228.7 | -19.6 | -20.4 |
| MDXG | 2021-08-27 | 6.0 | -221.2 | -19.0 | -19.7 |
| MDXG | 2021-08-26 | 6.0 | -217.9 | -18.7 | -19.4 |
| MDXG | 2021-08-25 | 6.0 | -217.7 | -18.7 | -19.4 |
| MDXG | 2021-08-24 | 6.0 | -219.3 | -18.8 | -19.5 |
MDXG Growth Metrics
- The year over year net cashflow from operations growth rate now stands at 32.31%.
- Its year over year cash and equivalents growth rate is now at 58.33%.
- Its 5 year net income to common stockholders growth rate is now at -164.5%.
The table below shows MDXG's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 258.615 | -1.982 | -16.421 |
| 2021-09-30 | 259.754 | -9.017 | -35.098 |
| 2021-06-30 | 260.983 | -19.965 | -83.167 |
| 2021-03-31 | 246.465 | -24.661 | -88.357 |
| 2020-12-31 | 248.234 | -30.263 | -83.328 |
| 2020-09-30 | 256.086 | -43.118 | -72.745 |
MDXG's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MDXG has a Quality Grade of C, ranking ahead of 64.26% of graded US stocks.
- MDXG's asset turnover comes in at 1.366 -- ranking 8th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows MDXG's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 1.366 | 0.833 | -0.426 |
| 2021-06-30 | 1.316 | 0.833 | -1.110 |
| 2021-03-31 | 1.302 | 0.842 | -1.153 |
| 2020-12-31 | 1.369 | 0.842 | -1.200 |
| 2017-09-30 | 1.597 | 0.881 | 0.532 |
| 2017-06-30 | 1.485 | 0.878 | 0.420 |
MDXG Price Target
For more insight on analysts targets of MDXG, see our MDXG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $16.17 | Average Broker Recommendation | 1.5 (Moderate Buy) |
MDXG Stock Price Chart Interactive Chart >
MDXG Price/Volume Stats
| Current price | $3.83 | 52-week high | $8.69 |
| Prev. close | $3.60 | 52-week low | $3.27 |
| Day low | $3.51 | Volume | 436,296 |
| Day high | $3.83 | Avg. volume | 558,092 |
| 50-day MA | $4.21 | Dividend yield | N/A |
| 200-day MA | $5.68 | Market Cap | 434.14M |
MiMedx Group, Inc (MDXG) Company Bio
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue.
Latest MDXG News From Around the Web
Below are the latest news stories about Mimedx Group Inc that investors may wish to consider to help them evaluate MDXG as an investment opportunity.
MiMedx Group Q4 2021 Earnings PreviewMiMedx Group (NASDAQ:MDXG) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close. The consensus EPS Estimate is $0.01 (+105.9% Y/Y) and the consensus Revenue Estimate is $63.69M (-6.4% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. Revenue... |
Peer-Reviewed Study Demonstrates Increased Cost-Effectiveness of MIMEDX Dehydrated Human Amnion Chorion Membrane (DHACM) in Lower Extremity Diabetic Ulcer (LEDU) Treatment Compared to Standard of CareUse of MIMEDX PURION® Processed DHACM Provided Improved Clinical Benefits, Shorter Average Length of Treatment and Increased Quality-Adjusted Life Years MARIETTA, Ga., Feb. 16, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the publication of a peer-reviewed study in the Journal of Wound Care evaluating the cost-effectiveness of the Company’s PURION® processed dehydrated human amnion/chorion |
Is MiMedx Group (NASDAQ:MDXG) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the... |
MIMEDX to Host Fourth Quarter 2021 Operating and Financial Results Conference Call on February 28MARIETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the fourth quarter ended December 31, 2021 after the market close on Monday, February 28, 2022. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 5:00 p.m. Eastern Time on the same day. The conference call can |
MiMedx rises as federal court dismisses securities class action lawsuit against companyNo summary available. |
MDXG Price Returns
| 1-mo | -2.30% |
| 3-mo | -22.63% |
| 6-mo | -48.03% |
| 1-year | -25.34% |
| 3-year | 140.13% |
| 5-year | -42.84% |
| YTD | -36.59% |
| 2021 | 33.04% |
| 2020 | 19.79% |
| 2019 | 323.46% |
| 2018 | -85.80% |
| 2017 | 42.33% |
Loading social stream, please wait...